Actively Recruiting
Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.
Led by Avistone Biotechnology Co., Ltd. · Updated on 2025-05-21
120
Participants Needed
1
Research Sites
155 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Efficacy and Safety Evaluation of Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.
CONDITIONS
Official Title
Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Ability to understand and willing to sign informed consent
- At least 18 years old
- Histologically or cytologically confirmed locally advanced or metastatic NSCLC (stage IIIB to IV)
- Untreated EGFRm-positive NSCLC with exon 19 deletion or L858R mutation and MET overexpression (IHC 3+)
- At least one measurable lesion by RECIST V1.1
- ECOG performance status 0 to 1
You will not qualify if you...
- Presence of ALK or ROS1 mutations
- Symptomatic and neurologically unstable central nervous system metastases or CNS disease requiring increased steroid doses
- Pregnant or nursing women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China, 510080
Actively Recruiting
Research Team
L
Liang Lin
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here